Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of Lymfactin® in patients with secondary lymphedema
associated with the treatment of breast cancer by comparing the effects of active study
treatment Lymfactin® to placebo. The study product will be administered in combination with a
surgical lymph node transfer operation. In addition, the safety and tolerability of the
Lymfactin® treatment will be evaluated.